CompletedNCT02684279
Longer-Term Dasotraline for Binge Eating
About this title
Dasotraline Binge Eating Disorder Extension Study
Read the official source — NCT02684279Medication studyAges 18–56United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 56 years.
- Listed locations
- Phoenix and 56 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: February 29, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 533
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 56 Years
- Official registry ID
- NCT02684279
- Official title
Show the full official title
An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix · Beverly Hills · Encino
52 more locations
- Garden Grove
- Newport Beach
- San Marcos
- Santa Ana
- Colorado Springs
- Denver
- Cromwell
- Fort Myers
- Jacksonville
- North Miami
- Orlando
- South Miami
- Alpharetta
- Atlanta
- Marietta
- Libertyville
- Indianapolis
- Prairie Village
- Wichita
- Belmont
- Boston
- Methuen
- Watertown
- Saint Charles
- Portsmouth
- Cherry Hill
- Princeton
- Mount Kisco
- New York
- Raleigh
- Akron
- Cincinnati
- Dayton
- Mason
- Oklahoma City
- Medford
- Portland
- Salem
- Allentown
- Anderson
- Greer
- Mt. Pleasant
- Memphis
- Nashville
- Austin
- Houston
- Plano
- San Antonio
- Murray
- Woodstock
- Herndon
- Seattle
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Dasotraline.
Who was this study for?
Listed age limits: 18 years to 56 years.
